Incyte Corp. closed 18.70% short of its 52-week high of $83.95, which the company achieved on November 8th.

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Incyte Corp. closed 16.64% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3 clinical study ...

The PocketMBA program embodies UD PCS’ commitment to equipping professionals with the skills necessary to excel in dynamic ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

Incyte shares rose Thursday after the drugmaker named Bill Meury its new CEO, effective immediately, to replace the retiring Hervé Hoppenot.